• Genomics & Informatics
• /
• 제6권4호
• /
• pp.181-191
• /
• 2008

RAS guanyl-releasing protein 3 (RasGRP3), a member of the Ras subfamily of GTPases, functions as a guanosine triphosphate (GTP)/guanosine diphosphate (GDP)-regulated switch that cycles between inactive GDP- and active GTP-bound states during signal transduction. Various growth factors enhance hepatocellular carcinoma (HCC) proliferation via activation of the Ras/Raf-1/extracellular signal-regulated kinase (ERK) pathway, which depends on RasGRP3 activation. We investigated the relationship between polymorphisms in RasGRP3 and progression of hepatitis B virus (HBV)-infected HCC in a Korean population. Nineteen RasGRP3 SNPs were genotyped in 206 patients with chronic liver disease (CLD) and 86 patients with HCC. Our results revealed that the T allele of the rs7597095 SNP and the C allele of the rs7592762 SNP increased susceptibility to HCC (OR=1.55, p=0.04 and OR=1.81${\sim}$2.61, p=0.01${\sim}$0.03, respectively). Moreover, patients who possessed the haplotype (ht) 1 (A-T-C-G) or diplotype (dt) 1 (ht1/ht1) variations had increased susceptibility to HCC (OR=1.79${\sim}$2.78, p=0.01${\sim}$0.03). In addition, we identified an association between haplotype1 (ht1) and the age of HCC onset; the age of HCC onset are earlier in ht1 +/+ than ht1 +/- or ht1 -/- (HR=0.42${\sim}$0.66, p=0.006${\sim}$0.015). Thus, our data suggest that RasGRP3 SNPs are significantly associated with an increased risk of developing HCC.

• 한국자원식물학회지
• /
• 제33권4호
• /
• pp.311-336
• /
• 2020

본 연구는 세종시 식물자원의 관리방안을 모색하고 식생관리와 희귀 및 멸종위기식물, 식물생태계 보존대책을 마련하기 위한 기초자료 제공에 있다. 연구결과는 다음과 같다. 세종시 일대에 분포하는 식물상은 104과 315속 462종 3아종 59변종 7품종의 총 531분류군으로 확인되었다. 희귀식물은 총 8과 8속 8종 8분류군으로 취약종(VU) 개박하 등 2분류군, 약관심종(LC) 쥐방울덩굴 등 4분류군, 자료부족종(DD) 큰개고사리 1분류군이 각각 출현하여 전체 식물종 중 1.5% 비율로 나타났다. 주목은 생태적으로 중요하지만 수형과 형태가 곧아 조경 식재용으로 개발하는 것이 필요할 것이다. 특산식물은 총 8과 9속 9종 9분류군으로 확인되었으며, 은사시나무, 오동나무는 산림경관용 군락으로 개발하는 것이 필요하다. 식물구계학적 특정식물은 V등급 자리공 등 2분류군, IV등급은 좀현호색 등 4분류군, III등급은 탱자나무 등 8분류군, II등급은 참개별꽃2분류군, I등급은 쇠고비 등 26분류군이 확인되었다. 귀화식물은 18과 38속 48종 1변종 49분류군으로 확인되었으며, 도시화지수(UI) 15.3%, 귀화율(NI) 8.7%로 분석되었다. 산림휴양과 치유에 필요한 유용식물은 식용이 199분류군으로 가장 높았으며, 목초용 193분류군, 약용 178분류군, 관상용 82분류군, 목재용 25분류군, 섬유용 18분류군, 염료용 9분류군 순으로 나타났다. 본 연구는 세종시 남부일대에 분포하는 식물상을 조사 및 분석하기 위해 수행하였다. 주로 조사된 자료는 생태적 가치에 집중된 경향이 있기 때문에 향후 이용객들이 식물에 대한 중요성을 인지할 수 있도록 보전용, 약용, 식용, 관상용 등 구분하여 보전에 대한 중요성 제고와 실생활과 밀접한 자원 발굴 등 자료 구축이 이루어진다면 세종시 남부일대의 식물상에 대한 자원적 및 생태적 가치가 높아질 것으로 판단된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권12호
• /
• pp.7367-7369
• /
• 2013

Background: Inoperable and metastatic hepatocellular carcinoma (HCC) is associated with a poor prognosis and low chemotherapeutic efficiency. Sorafenib is an oral multi-kinase inhibitor exerting its effects via the RAF/MEK/ERK pathway, vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor beta (PDGFR-${\beta}$) tyrosine kinases. Randomized studies have shown a significant contribution of sorafenib to life expectancy and quality of life of cancer patients. The aim of the present study is to evaluate the efficacy and side effects of sorafenib therapy in Turkey. Materials and Methods: Data for 103 patients (82 males, 21 females) receiving sorafenib therapy in 13 centers from February 2008 to December 2012 were evaluated. Median age was 61 years and median ECOG performance status was 1 (range: 0-2). 60 patients (58%) had hepatitis B, 15 patients (15%) had hepatitis C infection and 12 patients (12%) had a history of alcohol consumption. All of the patients had Child scores meeting the utilization permit of the drug in our country (Child A). Results: A total of 571 cycles of sorafenib therapy were administered with a median of four per patient. Among the evaluable cases, there was partial response in 15 (15%), stable disease in 52 (50%), and progressive disease in 36 (35%). Median progression-free survival was 18 weeks and median overall survival was 48 weeks. The dose was reduced only in 6 patients and discontinued in 2 patients due to grade 3-4 toxicity, 18 patients (17%) suffering hand-foot syndrome, 7 (7%) diarrhea, and 2 (2%) vomiting. Conclusions: This retrospective study demonstrated better efficacy of sorafenib therapy in patients with advanced HCC compared to the literature while progression-free survival and overall survival findings were comparable. The side effect rates indicate that the drug was tolerated well. In conclusion, among the available treatment options, sorafenib is an efficient and tolerable agent in patients with inoperable or metastatic HCC.